Archive · 11 Nov 2025
New Experimental Pill Enlicitide Shows Promise in Cutting "Bad" Cholesterol
Imagine your body has a type of fat in your blood called cholesterol.
Some of it is 'good' and some is 'bad'.
Too much 'bad' cholesterol can lead to heart problems.
Doctors already have medicines to help, like pills called statins and shots.
But some people don't get enough benefit from statins, or they can't take them.
The shots work well but can be expensive and tricky to get.
Now, scientists are testing a new pill called enlicitide.
In a big study, this pill helped lower the 'bad' cholesterol by a lot, almost as much as the shots.
It's a daily pill, so it's easier to take than shots.
This could be great news for many people, especially where expensive medicines are hard to get.
However, we still need to learn more about its long-term safety and if it truly helps prevent heart attacks.
Doctors will need to figure out the best way to use it with other treatments.
The experimental oral drug enlicitide reduced LDL-C ('bad' cholesterol) by approximately 55.8% in a Phase 3 trial.
A post-hoc analysis indicated a potential LDL-C reduction of up to 59.7% with enlicitide.
Enlicitide belongs to the PCSK9 inhibitor class and offers a potential alternative to injectable therapies.
The drug's safety profile in the trial was comparable to placebo, with no major safety signals identified.
While promising for patient adherence and access, questions remain regarding long-term cardiovascular outcomes, safety, and cost before widespread adoption.
- Who
- The investigational drug enlicitide and 2,912 adult participants in the CORALreef Lipids Phase 3 trial.
- What
- Enlicitide, a new oral PCSK9 inhibitor, demonstrated a significant reduction in 'bad' cholesterol (LDL-C) in a Phase 3 trial.
- When
- The trial's primary analysis was at 24 weeks, with favorable safety data also observed at one year.
- Where
- The trial involved adults at risk of or with established atherosclerotic cardiovascular disease (ASCVD). Implications are particularly noted for India.
- Why
- To address the unmet need for effective, convenient, and accessible treatments for high LDL-C, especially for patients intolerant or resistant to statins, and those for whom injectable therapies are not feasible.
Potential Benefits of Enlicitide
Unanswered Questions and Caveats
Efficacy in Lowering LDL-C
Potential Benefits of Enlicitide
Enlicitide demonstrated significant reductions in LDL-C, up to 59.7% in post-hoc analysis, comparable to existing injectable PCSK9 inhibitors.
Unanswered Questions and Caveats
The primary data is based on surrogate endpoints (LDL-C reduction), and it remains to be seen if this translates to a reduction in actual cardiovascular events like heart attacks and strokes.
Patient Access and Convenience
Potential Benefits of Enlicitide
As an oral daily pill, enlicitide offers potential for improved patient adherence and broader access compared to costly and inconvenient injectable therapies, especially in resource-limited settings like India.
Unanswered Questions and Caveats
Regulatory approvals, final cost, and real-world accessibility will ultimately determine its utility and whether it can truly democratize access to potent LDL-C lowering.
Safety Profile
Potential Benefits of Enlicitide
The safety profile in the Phase 3 trial was comparable to placebo, with low discontinuation rates due to adverse events observed at 24 weeks and one year.
Unanswered Questions and Caveats
Longer-term safety data is still pending, and comprehensive regulatory scrutiny will be required before widespread approval and use.
- Drug Name
- Enlicitide
- Drug Class
- PCSK9 inhibitor (oral)
- Trial Name
- CORALreef Lipids (Phase 3)
- Primary Efficacy
- Reduced LDL-C by 55.8% at 24 weeks (mean reduction)
- Maximum Efficacy
- Up to 59.7% reduction in LDL-C (post-hoc analysis)
- Trial Duration for Safety Data
- 24 weeks and one year
- Patient Population
- Adults at risk of or with established ASCVD, on background lipid-lowering therapy or statin-intolerant